Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01809600
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:16.802704+00:00
Published At
2017-02-24T00:00:00+00:00
Record Updated At
2017-02-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Burkitt\u0027s Lymphoma", "High-grade B-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-02-24"
protocolSection.identificationModule.nctId
"NCT01809600"
protocolSection.identificationModule.officialTitle
"Rituximab-Containing Immunochemotherapy for Burkitt\u0027s Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Burkitt's Lymphoma (protocolSection.conditionsModule.conditions)
  • High-grade B-cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.